Oxeltis ranked one of the fastest growing companies in the 2015 Deloitte In Extenso Technology Fast 50
Secured 30th position after a 559% revenue growth between 2011 and 2014, expects 50% increase in 2014-2015
Oxeltis has built a loyal international client base with itshighly responsive service, its non-disclosure policy and strong scientific expertise in niche areas of medicinal chemistry
Montpellier, France, November 26, 2015 – Oxeltis, a medicinal chemistry and custom synthesis company, today announces that it has been ranked 30th in the 2015 Deloitte In Extenso Technology Fast 50 for France. The ranking is an award program for the fastest-growing technology businesses, selected on the rate of revenue growth over the last four financial years. Oxeltis grew by 559% between 2011 and 2014, securing its ranking as 30th amongst the 460 businesses that applied this year.
Founded in 2010, Oxeltis specializes in the development of small-scale custom synthesis and in hit and lead optimization programs; predominantly in the areas of antivirals, antibiotics and anticancer agents. The company has grown exponentially over the last four years after developing its custom synthesis business in a small number of niche areas such as the synthesis of natural molecule analogues for therapeutic use, especially anti-infective drugs. Its experienced team gives the company a distinct advantage in the highly competitive international market. Oxeltis has been able to win new business against European and Asian competitors by controlling overall operating costs and developing a simple and responsive organizational structure.